Циркулирующие антитела к рецептору фосфолипазы а 2 при первичной мембранозной нефропатии

Vladimir Dobronravov, Sergey Vladimirovich Lapin, Н. М. Лазарева et al. · Nephrology (Saint-Petersburg) · 2012

AIM OF THE STUDY: evaluation of clinical significance of circulating antibodies to transmembrane phospholipase A2 M-type receptor of podocytes (anti-PLA2R Ab) in patients with primary membranous nephropathy (MN) on the top of already administered therapy. PATIENTS AND METHODS. 20 proved or prospectively observed patients with primary membranous nephropathy on symptomatic treatment with or without immunosuppressive therapy were included into observational study. Clinical data obtained at the moment of biopsy and during prospective follow-up included: gender, age, serum creatinine and albumin concentration, daily proteinuria (DP), AP, estimated glomerular filtration rate. Median of prospective follow-up was 525 (265- 1030) days. Anti-PLA2R Ab of IgG class was detected after treatment by indirect immunofluorescence. RESULTS. Anti-PLA2R Ab was found in 7 patients (group 1) and was absent in 13 (group 2) of 20 patients studied. There were no differences in level of proteinuria, albuminemia, AP and renal function at the time of biopsy. There were no significant changes in level of proteinemia, albuminemia and cases of clinical remissions in group 1 during treatment; in group 2 DP decreased significantly in contrast to initial value, serum albumin level practically normalized and clinical remission was achieved in all patients (3 cases – partial, 10 cases – complete). All cases of complete remission were observed after corticosteroids and cyclosporine combined therapy. CONCLUSION. Absence of anti-PLA2R Ab in patients on therapy is associated with achievement of clinical remission of primary MN; this test can be applied for monitoring of the disease activity, evaluation of treatment efficacy and prognosis.

Cited by 0 works.

Authors